Clinical trials: Cerebral Small Vessels Disease
Intracerebral Hemorrhage
Minimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage--Small Hemorrhage Evacuation (MIRACLE-S)
The objective of this study is to determine whether minimally invasive soft channel brain hemorrhage evacuation (scMIS), compared to usual care, leads to superior functional recovery as measured by utility-weighted modified…
- Trial name
- MIRACLE-S (NCT06688162)
- Testing
- Usual Care, Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Capital Medical University
Dementia, Alzheimer Disease
A Longitudinal Multidimensional Population Study on Brain Aging
Longitudinal observational study of cognitive functions, physical health and biological parameters in the whole population living in Abbiategrasso born between 1935 and 1939,1773 subjects, followed for six years in order to know…
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- InveCeAb (NCT01345110)
- Where
- Italy
- Volunteers
- 1,321 people
- Sponsor
- Fondazione Golgi Cenci
Fabry Disease
Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease
This is a Phase II, open-label study designed to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of AL01211 in male subjects with classic Fabry disease who have never received any treatment (eg.
- Trial name
- NCT06114329
- Testing
- AL01211
- Where
- 6 sites in China
- Volunteers
- 16 people
- Sponsor
- AceLink Therapeutics, Inc.
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS)
The ANCA Vasculitis Questionnaire (AAV-PRO©)
The aim of this project is to develop a disease specific patient reported outcome measure (PROM) for patients with AAV (the AAV-PRO).
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG)
- Trial name
- AAV-PRO (NCT02507024)
- Testing
- Online questionnaire
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- University of Pennsylvania
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Fabry Disease
Fabry Disease Registry & Pregnancy Sub-registry
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status.
- Trial name
- NCT00196742
- Where
- 284 sites in United States, Argentina and 42 more
- Volunteers
- 9,000 people
- Sponsor
- Genzyme, a Sanofi Company
Fabry Disease
An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
This study will continue to evaluate the safety of using intravenous doses of Replagal for two patients with Fabry disease. Fabry disease is a genetic disorder inherited as an X-linked recessive trait.
- Trial name
- NCT00357786
- Testing
- Replagal agalsidase alfa, Replagal
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer Disease, CVA (Cerebrovascular Accident)
Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD
Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA \& HSA, is authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type.
- Trial name
- NCT02444637
- Testing
- Rivastigmine
- Where
- Singapore
- Volunteers
- 100 people
- Sponsor
- National Neuroscience Institute
Wegener's Granulomatosis, Renal Limited Vasculitis
Anti-Cytokine Therapy for Vasculitis
The purpose of this study is to determine whether Infliximab (monoclonal anti-tumour necrosis factor alpha antibodies) are safe and effective in the treatment of anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis.
- Conditions
- Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis
- Trial name
- ACTIVE (NCT00753103)
- Testing
- Infliximab, Cyclophosphamide, Prednisolone
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Fabry Disease
Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease
This is a first-in-human study for the treatment of Fabry disease. Eligible patients will have an autologous stem cell transplantation using CD34+ cells that are transduced with the lentivirus vector containing the human…
- Trial name
- NCT02800070
- Testing
- Lentivirus Alpha-gal A transduced stem cells
- Where
- 3 sites in Canada
- Volunteers
- 5 people
- Sponsor
- University Health Network, Toronto
Leukodystrophy, White Matter Disease
The Myelin Disorders Biorepository Project
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects.
- Conditions
- Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome
- Trial name
- MDBP (NCT03047369)
- Where
- 23 sites in United States
- Volunteers
- 12,000 people
- Sponsor
- Children's Hospital of Philadelphia
Autoimmune Diseases, Non-small Cell Lung Cancer
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
The purpose of this study is to explore the safety, tolerability and activity of Nivolumab, a PD-1 inhibitor, in cohorts of patients with autoimmune disease.
- Conditions
- Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis
- Trial name
- NCT03656627
- Testing
- Nivolumab
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance Foundation Trials, LLC.
Cerebral Small Vessel Disease, Vascular Cognitive Impairment
Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease
This study will evaluate whether personalized intermittent theta burst stimulation (iTBS), a form of noninvasive transcranial magnetic stimulation, can safely improve cognitive function in people with cognitive impairment related…
- Trial name
- NCT07891650
- Testing
- Active Personalized Intermittent Theta Burst Stimulation
- Where
- 3 sites in China
- Volunteers
- 160 people
- Sponsor
- Xuanwu Hospital, Beijing
Cerebrovascular Accident, Hypercholesterolemia
Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.
- Trial name
- LA BICHAT (NCT00163150)
- Testing
- Atorvastatin
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Aortitis, Cutaneous Vasculitis
VCRC Tissue Repository
The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies.
- Conditions
- Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis
- Trial name
- NCT02967068
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Mild Cognitive Impairment
Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD
This study aimed to explore the efficacy and safety of Ginkgo Biolba Extract fifty in treating mild cognitive impairment associated with cerebral small vessel disease (CSVD).
- Trial name
- GRACE (NCT06495476)
- Testing
- Ginkgo biloba extract 50 dropping pills, Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Beijing Tiantan Hospital
Stroke
Step Test and Six Minute Walk Test in Stroke
The purpose of this study is to investigate the viability of using the Step Test (ST) in stroke patients, and to compare the functional performance of the physiologic variables in stroke patients during ST and Six Minute Walk…
- Trial name
- NCT01436630
- Testing
- Step Test and Six Minute Walk.
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Faculdades Metropolitanas Unidas
Fabry Disease
Quality of Life in Adults With Untreated Fabry Disease in Sweden (QoLUF)
Fabry disease is a rare, inherited condition that can affect multiple organs, including the heart, kidneys, and nervous system. Many people with Fabry disease live for a period of time without receiving disease-specific…
- Trial name
- QoLUF (NCT07560956)
- Testing
- Qualitative Interview
- Where
- Sweden
- Volunteers
- 35 people
- Sponsor
- Vastra Gotaland Region
Cerebral Small Vessel Disease
Neural Correlates (EEG and fMRI) of Gait in Small Vessel Disease
What is the purpose of this study? This observational study is being done to understand how cerebral small vessel disease (SVD) affects walking and balance.
- Trial name
- doesn't exist (NCT07372937)
- Testing
- No Intervention: Observational
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital